Next-gen psychedelics producers Mindset Pharma Inc. (OTCQB: MSSTF) and PharmAla Biotech Holdings Inc. have entered into an exclusive sales agreement making PharmAla the sole global reseller of Mindset’s current Good Manufacturing Process (cGMP) psilocybin to licensed clinical researchers.

Regarding Mindset’s development of a patent-pending, scalable psilocybin synthesis technology, the company’s CEO James Lanthier says he recognizes that a cost-effective supply of first-generation psychedelics is “essential” to the development of the medical psychedelic space.

Mindset has recently completed the production of a large batch of cGMP psilocybin …

Full story available on Benzinga.com